Source: Frontiers in Lab on a Chip Technologies, by Qasaimeh, Mohammad Ameen; Glia, Ayoub; Deliorman, Muhammedin. AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- The review describes microfluidic enrichment paired with AFM to measure individual circulating tumor cell stiffness, adhesion, deformation, and viscoelasticity.
- Published studies include direct AFM measurements of individual patient-derived CTCs and automated analysis after microfluidic enrichment in model rare-cell mixtures.
- Clinical validation is limited, and the review found no direct AFM characterization of intact patient-derived CTC clusters.
A review of circulating tumor cells, or CTCs, argues that pairing microfluidics with atomic force microscopy could turn liquid biopsy into a more functional readout of cancer behavior. CTCs are tumor-derived cells that enter the bloodstream, where they may travel alone or in multicellular clusters during the process of metastasis. The review focuses on their mechanobiology, meaning the way physical properties such as stiffness, deformability, adhesion, and time-dependent shape recovery relate to cell state. Microfluidic devices can enrich and handle these rare cells from blood, while atomic force microscopy, or AFM, can probe individual cells with nanoscale precision in liquid. Together, the methods may link a cell's mechanical signature to its molecular makeup, including its cytoskeleton, membrane components, surface sugars, and receptors. The authors describe promising workflows for capturing viable CTCs, locating them automatically, and measuring their response to forces or treatment. But the article is a review of an emerging technical field, not evidence that an integrated platform is ready for clinical use. Direct measurements of patient-derived CTCs remain limited, and the review found no published direct AFM characterization of intact CTC clusters from patients.
Why CTC Mechanics Are of Interest
Cancer does not progress through genetic changes alone. Tumor cells also reorganize their internal scaffolding, alter how they attach to neighboring cells, and change how easily they squeeze through confined spaces such as blood vessels.
A useful analogy is a traveler packing for a difficult journey. To leave a tumor, enter circulation, survive fluid forces, and establish a new site, a cell may need to adjust both its internal structure and its outer grip on the environment. Measurements of stiffness or adhesion could therefore add information that cell counting alone cannot provide.
A Rare and Diverse Target
CTCs are attractive because they can be sampled from blood, making them part of a liquid biopsy, a test that examines tumor-related material without removing tissue directly from a tumor. They may offer a window into tumor phenotypes that evolve during disease and treatment.
They are also difficult to study. CTCs are rare among the many blood cells in a sample, and they are heterogeneous, meaning cells from the same patient may differ in size, molecular markers, physical behavior, and metastatic potential. Clusters add another layer of complexity because their cell-to-cell connections may help determine how they behave in circulation.
What Microfluidics Contributes
Microfluidics uses channels and structures that guide very small volumes of fluid, much like a carefully designed system of tiny plumbing. In CTC research, these devices can enrich, capture, position, and recover cells while preserving their viability for later measurements.
The review covers physical approaches that separate cells by properties such as size or deformability, as well as affinity-based methods that use molecular binding to capture chosen cells. It also discusses cluster-preserving designs, open-space systems, artificial intelligence-assisted strategies, and reversible device assembly, which can make it easier to access captured cells after sorting.
What AFM Adds at the Single-Cell Scale
AFM measures forces by bringing a tiny probe into contact with a sample and recording how the probe bends or moves. Like pressing lightly on a piece of fruit to judge its firmness, it can estimate a cell's apparent elasticity, but at far smaller scales and with controlled force.
For CTCs, AFM can measure deformation, adhesion, viscoelastic response, and nanoscale surface architecture in liquid. Viscoelasticity describes material behavior that is partly spring-like and partly time-dependent, so a cell may resist a push immediately but continue changing shape after the force is applied.
Connecting Mechanical and Molecular Clues
The review emphasizes that a mechanical measurement is most informative when considered alongside molecular context. Cytoskeletal proteins help organize the cell's internal framework, membrane lipids help shape the cell boundary, and surface glycans, or sugar-containing structures, and receptors can influence cell interactions.
Functionalized AFM probes offer one way to make that connection. These probes can be coated with molecules designed to recognize a target on the cell surface, allowing researchers to measure molecule-specific interactions rather than only broad physical properties. Advanced mapping modes and fluidic probes could further expand what is measured across a cell surface.
Early Signs of Feasibility
The studies surveyed by the review show that direct AFM measurements of individual patient-derived CTCs are feasible. The literature also includes automated analysis after microfluidic enrichment in model mixtures containing rare cells.
Those demonstrations matter because the main challenge is not simply measuring a cultured cancer cell on a dish. A clinically useful workflow would need to find rare tumor cells within blood, verify their identity, retain them in suitable condition, and produce comparable measurements across samples and laboratories.
Where the Evidence Stops
The review is clear about the limits of the current evidence. Many integrated microfluidic and AFM workflows rely on cultured cells or spiked samples, in which known cancer cells are deliberately added to a blood-like mixture rather than recovered from patients.
Clinical evidence remains limited, and the authors did not identify direct AFM characterization of intact patient-derived CTC clusters in the literature reviewed. That absence is important because clusters may not behave like isolated cells, and separating or handling them could itself alter the physical traits researchers hope to measure.
Why This Matters
Most CTC applications have centered on enumeration, or counting cells. Integrated microfluidic-AFM systems could potentially move beyond that count toward functional mechanobiological analysis, asking how an individual tumor cell responds to forces and whether those responses change with phenotype or treatment.
That possibility is especially relevant for treatment-response studies. If mechanical signatures track invasive potential, phenotypic state, or response to therapy, they could someday complement molecular tests. The review does not establish that such signatures can predict patient outcomes, but it lays out the technical pieces needed to test that proposition rigorously.
What Translation Will Require
For these approaches to move toward patient studies, the authors call for confirmation that measured cells are truly tumor-derived, standardized methods for data acquisition and reporting, greater throughput, and independent patient-cohort validation. They also stress an appropriate statistical hierarchy that accounts for patients, cells, and measurement curves rather than treating every force trace as an independent clinical observation.
The next phase is likely to be less about adding another instrument and more about building dependable end-to-end workflows. If researchers can preserve rare patient CTCs, measure them reproducibly, connect mechanics to molecular identity, and validate findings across cohorts, liquid biopsy could provide a richer view of cancer cells in transit.